The contentious role of intellectual property in cryptographic standardisation

No items found.
​
January 12, 2026

A good cryptologist, in similarity to a good patent attorney, is paranoid. One of the largest bouts of paranoia that has (probably rightfully) infected the field of cryptology is the threat posed by a quantum computer on public-key encryption. Using Shor’s algorithm, a quantum computer may break the ubiquitous public-key cryptosystems based on the order finding problem, such as RSA and elliptic-curve cryptography. Consequently, a substantial amount of cryptographic research has thus been directed towards developing quantum-safe alternatives for public-key cryptography, in a field known as Post-Quantum Cryptography (PQC). In 2024, the National Institute of Standards and Technology (NIST) published the first PQC standards, affectionately dubbed FIPS 203, 204 and 205. This article examines the selection process from an intellectual property perspective and highlights some uncommon, though not unprecedented, features of the path to cryptographic standardisation.

The usual selection process involves multiple rounds of public evaluation. In the case of PQC, NIST called for submissions in 2016, admitted 69 complete candidates into the first round, which were narrowed down to finalists and alternates in subsequent rounds, and issued the first standards in 2024. Typically, researchers submit cryptosystems, often accompanied by intellectual property statements. The community evaluates security, performance, and implement ability, and NIST publishes rationales and drafts for public comment before finalisation. Researchers prioritise the dissemination of standards and secure communications and therefore usually permit free use of potentially patentable subject matter (such as implementations of protocols). However, history provides notable exceptions, which we will explore below.

Historical examples: RSA and ECC

The encumbrance of patents does not automatically disqualify a specific cryptosystem from standardisation, but standard setting organisations and government agencies now typically require either royalty free or FRAND (fair, reasonable, and non discriminatory) licenses, or at minimum explicit disclosures, to avoid later disputes. The case of RSA is illustrative as a historic example as to why. The US patent 4 405 829 was granted in 1983 to MIT disclosing the encryption scheme, with a filing date in 1977 ​[1]​. An academic publication by the inventors had been published in 1976, which sparked many implementations of the RSA cryptosystem into software. After the patent was granted, the company RSA Security together with MIT started enforcing it, which likely stifled wide adoption of the cryptosystem but made RSA a commercial success. The patent was set to expire in September 2000 but was surprisingly released two weeks early into the public domain as a “symbolic next step in the evolution of this market” ​[2]​, perhaps to garner goodwill in the community.

The standardisation of elliptic-curve cryptography (ECC) has long been an area of uncertainty regarding intellectual property. ECC was never widely adopted despite offering advantages such as smaller key sizes in comparison to RSA. According to cryptologist Daniel J. Bernstein, “popular rumour states that elliptic-curve cryptography is a patent minefield” ​[3]​. This perception likely arose from patents covering efficient implementation techniques for ECC, although alternative implementations existed that were not patented ​[4]​. This contrasts with RSA, where the cryptosystem itself was patented. Although the NSA sought to license the relevant implementation details for standardisation, and elliptic-curve Diffie-Hellman was later incorporated into NIST standard SP 800-56Ar3, ECC never achieved broad adoption. It remains unclear whether the rumour, the patents or competition with RSA were decisive, although all three factors likely played a role.

A shift in the approach

Turning to the present and the standardisation of PQC, NIST appears to have taken a forward-looking approach to intellectual property rights. A notable feature of the PQC rollout is NIST’s facilitation of patent licences for the key encapsulation mechanism Kyber, part of FIPS 203. In response to concerns about patents claiming aspects of lattice-based key encapsulation, NIST negotiated two royalty-free licences covering United States and French patent portfolios. The US portfolio, with PCT application number WO2013152725A1, concerns a key-exchange mechanism using pairing with errors, building on the principle of learning with errors, the cryptographic primitive used in Kyber. The French portfolio, stemming from patent FR2956541B1, relates to a method for secure communication that may be used for key exchange or messaging in resource-constrained environments.

The licensors agreed to suspend enforcement rights on a royalty-free basis for implementations of Kyber in accordance with NIST’s specification ​[5]​. Notably, only excerpts of the licence have been released, so details such as any licence fees remain unknown. This proactive approach is important because standards depend on certainty. Implementers require clear intellectual property terms in addition to clear technical specifications. By addressing these issues, NIST reduces legal friction and facilitates widespread adoption of secure communication methods for governments and individuals alike.

Conclusion

These examples demonstrate that intellectual property rights play a vital role in cryptography and are often contentious. Some argue that patents should be avoided entirely, but the reality is that patents can incentivise research and do not necessarily impede adoption if managed appropriately. Compared to the telecommunications industry, where standard-essential patenting and licensing is routine, cryptography has historically handled such matters on an ad hoc basis. However, greater awareness and foresight are emerging. Perhaps the future of cryptography will also embrace FRAND licensing on a broad scale?

​​References

​​

​[1]  ​E. Roberts, “RSA Public Key Encryption,” Stanford University, 5 June 2000. [Online]. Available: https://cs.stanford.edu/people/eroberts/cs201/projects/software-patents/rsa.html. [Accessed 19 December 2025].

​[2]  ​RSA, “RSA Security Releases RSA Encryption Algorithm into Public Domain,” 6 September 2000. [Online]. Available: https://web.archive.org/web/20071120112201/http://www.rsa.com/press_release.aspx?id=261. [Accessed 19 December 2025].

​[3]  ​D. J. Bernstein, “Irrelevant patents on elliptic-curve cryptography,” [Online]. Available: https://cr.yp.to/ecdh/patents.html. [Accessed 7 January 2026].

​[4]  ​RSA Laboratories, “Are elliptic curve cryptosystems patented?,” [Online]. Available: https://web.archive.org/web/20130524001754/http://www.rsa.com/rsalabs/node.asp?id=2325. [Accessed 7 January 2026].

​[5]  ​National Institute of Standards and Technology, “NIST PQC License Summary and Excerpts,” [Online]. Available: https://csrc.nist.gov/csrc/media/Projects/post-quantum-cryptography/documents/selected-algos-2022/nist-pqc-license-summary-and-excerpts.pdf. [Accessed 7 January 2026]. ​

‍

The Latest Thought Leadership pieces in the Content Hub

Analysis of Intel’s cellular patent portfolio
September 20, 2019
Intel has built a cellular portfolio of 5G patent assets at some pace. The industry should take note, says James Seymour in this article in the September 2019 issue of Intellectual Property Magazine.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​